Novo Nordisk (NVO.US) soared in pre-market trading, with Ozempic's cardiovascular protection effectiveness superior to older Lilly drugs.

date
18/09/2025
According to the Securities Times app, Novo Nordisk (NVO.US) saw its stock price achieve the largest single-day increase in the past month. The reason for this is that its diabetes blockbuster drug Ozempic outperformed Eli Lilly's (LLY.US) older drug Trulicity in a real-world study involving some patients in the United States.